NewLink Genetics
Now Lumos Pharma, Inc.
Now Lumos Pharma, Inc.
NewLink Genetics, now known as Lumos Pharma, Inc., is a pioneering biopharmaceutical company established in 1999. The company's core focus lies in the discovery, development, and commercialization of innovative immuno-oncology product candidates, aiming to enhance the quality of life for cancer patients. Operating at the forefront of immuno-oncology treatments, NewLink Genetics is propelled by a diverse team of industry professionals and physician-scientists, shaping the future of cancer care. The company draws inspiration from personal cancer stories, driving its determined research and development efforts to advance treatment options. With a vision to revolutionize the cancer treatment landscape, NewLink Genetics aspires to create a meaningful impact on the daily lives of patients. The company received a noteworthy $7.50M Series D investment on July 21, 2009, strengthening its position in the biotechnology and healthcare industries. Based in the United States, the company continues to demonstrate dedication to its mission, backed by strategic investments and a compelling vision for the future.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $7.50M | - | 21 Jul 2009 | |
| Series C | $17.00M | 5 |
|
31 Jan 2008 |
| Series B | $8.24M | 4 | Iowa Capital Management, Midwest Oilseeds +2 | 07 Sep 2007 |
| Series A | $850.00K | - | 13 Feb 2002 |
No recent news or press coverage available for NewLink Genetics.
We care about your data, and we'd love to use cookies make your experience better.
